Viewing data from:

NEUTREXIN

NDA

TRIMETREXATE GLUCURONATE | N020326 | MEDIMMUNE ONCOLOGY INC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

3 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 25MG BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Dec 17, 1993

No patent or exclusivity listings for this strength.

#002 — EQ 200MG BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Jul 31, 1998